Markets:

Overview

News

Currencies

International

Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

108.81 -2.44 (-2.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The Pack

March 27, 2025

Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers.

Via StockStory

Q4 Testing & Diagnostics Services Earnings: RadNet (NASDAQ:RDNT) Impresses

March 26, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting...

Via StockStory

Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries

March 25, 2025

From Guardant Health, Inc.

Via Business Wire

1 Healthcare Stock on Our Watchlist and 2 to Turn Down

March 20, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and...

Via StockStory

Topics Stocks

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX)

March 14, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst...

Via StockStory

1 Stock Under $50 with Solid Fundamentals and 2 to Turn Down

March 13, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue ↗

March 11, 2025

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision.

Via Benzinga

Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday ↗

March 11, 2025

Via Benzinga

Guardant Health Receives ADLT Status From CMS for Shield Blood Test

March 11, 2025

From Guardant Health, Inc.

Via Business Wire

Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled ↗

March 10, 2025

Small caps took another step down this past week as geopolitical events dampened sentiment.

Via Talk Markets

Topics ETFs Stocks / Equities

Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

March 05, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue

March 03, 2025

Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 30.2% year on year to $201.8 million. Its GAAP loss of $0.90 per share was 12.4%...

Via StockStory

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 28, 2025

From Guardant Health, Inc.

Via Business Wire

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

February 27, 2025

From Guardant Health, Inc.

Via Business Wire

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday? ↗

February 21, 2025

Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.

Via Benzinga

Guardant Health Tops Q4 Revenue Forecast ↗

February 20, 2025

The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.

Via The Motley Fool

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

February 20, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in Upcoming Investor Conferences

February 10, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Debt Exchange Transactions

February 07, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

January 30, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program

January 30, 2025

From Guardant Health, Inc.

Via Business Wire

Okla And Rigetti Computing Are Among Top 8 Mid Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio? ↗

January 26, 2025

Top performers in last week's mid-cap stocks: Oklo Inc., Tempus AI, Himax Tech, Super Group, NuScale Power, WNS Holdings, Guardant Health, Rigetti Computing.

Via Benzinga

Topics Artificial Intelligence

Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development

January 23, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test ↗

January 21, 2025

Guardant Reveal test receives expanded Medicare coverage for colorectal cancer recurrence monitoring, enhancing revenue potential and clinical adoption.

Via Benzinga

Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone ↗

January 21, 2025

The company is working to expand the uses and reimbursement for its blood-based tests for cancer.

Via Investor's Business Daily

Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday ↗

January 21, 2025

Via Benzinga

Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients

January 21, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development

January 16, 2025

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

January 13, 2025

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Guardant Health, Inc. - Common Stock (NQ:GH)

All News about Guardant Health, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today